Wan Suxin, Zhu Jia-Quan, Wang Lihua
Department of Pharmacy, Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.
Fengdu General Hospital, Pharmaceutical Department, Chongqing, China.
Front Immunol. 2025 Aug 14;16:1537972. doi: 10.3389/fimmu.2025.1537972. eCollection 2025.
With the increasing challenge of antibiotic resistance, polymyxin E is considered a last-line treatment option for infections caused by highly resistant bacteria. However, its use may lead to various adverse reactions, such as nephrotoxicity, neurotoxicity, and allergic reactions.
This study describes a case of polymyxin E-associated leukopenia in a 50-year-old female treated for infection. During polymyxin E therapy, the patient developed leukopenia, with white blood cell (WBC) counts declining from 5.65×10/L to 0.91×10/L. The condition resolved progressively after the cessation of polymyxin E. The Naranjo scale yielded a score of 7 for polymyxin E-associated leukopenia, while other medications scored ≤0. The WHO-Uppsala Monitoring Centre (WHO-UMC) causality classification system categorized the relationship as 'probable.'
These findings suggest that polymyxin E likely induces leukopenia, emphasizing the need for rigorous WBC monitoring during treatment and prompt discontinuation when hematologic abnormalities emerge to minimize patient health risks.
随着抗生素耐药性挑战的不断增加，多粘菌素E被视为治疗高度耐药菌感染的最后一线治疗选择。然而，其使用可能导致各种不良反应，如肾毒性、神经毒性和过敏反应。
本研究描述了一例在接受感染治疗的50岁女性中发生的多粘菌素E相关性白细胞减少症。在多粘菌素E治疗期间，患者出现白细胞减少，白细胞（WBC）计数从5.65×10⁹/L降至0.91×10⁹/L。停用多粘菌素E后病情逐渐缓解。对于多粘菌素E相关性白细胞减少症，Naranjo量表评分为7分，而其他药物评分为≤0分。世界卫生组织-乌普萨拉监测中心（WHO-UMC）因果关系分类系统将该关系归类为“很可能”。
这些发现表明多粘菌素E可能诱发白细胞减少，强调在治疗期间需要严格监测白细胞，当出现血液学异常时及时停药，以将患者健康风险降至最低。
